Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Northwell Health
University of Texas Southwestern Medical Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute, Egypt
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institut Claudius Regaud
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
BioNTech SE
All India Institute of Medical Sciences
Mucosa Innovations, S.L.
University of Cincinnati
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Illinois at Chicago
Institut Claudius Regaud
University of Texas Southwestern Medical Center
Boehringer Ingelheim
Canadian Cancer Trials Group
All India Institute of Medical Sciences
National Cancer Institute (NCI)
Montefiore Medical Center
Montefiore Medical Center
Astellas Pharma Inc
Providence Health & Services
The New York Proton Center
Association Francaise pour la Recherche Thermale
University Hospitals Coventry and Warwickshire NHS Trust
Medical University of South Carolina
University of Arizona
Providence Health & Services
University of Chicago
GlaxoSmithKline
SWOG Cancer Research Network
Medical University of South Carolina
Seagen Inc.
USWM, LLC (dba US WorldMeds)
Seagen Inc.
West China Hospital
Pfizer
National Institutes of Health Clinical Center (CC)
University of Alberta
PDS Biotechnology Corp.